1. Home
  2. DBVT vs GFUZ Comparison

DBVT vs GFUZ Comparison

Compare DBVT & GFUZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo DBV Technologies S.A.

DBVT

DBV Technologies S.A.

N/A

Current Price

$9.02

Market Cap

692.2M

Sector

Health Care

ML Signal

N/A

GFUZ

General Fusion Group Ltd. Common Shares

N/A

Current Price

$4.24

Market Cap

687.0M

Sector

Utilities

ML Signal

N/A

Company Overview

Basic Information
Metric
DBVT
GFUZ
Founded
2002
2002
Country
France
Canada
Employees
90
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Electric Utilities: Central
Sector
Health Care
Utilities
Exchange
Nasdaq
Nasdaq
Market Cap
692.2M
687.0M
IPO Year
2014
2025

Fundamental Metrics

Financial Performance
Metric
DBVT
GFUZ
Price
$9.02
$4.24
Analyst Decision
Buy
Analyst Count
7
0
Target Price
★ $36.51
N/A
AVG Volume (30 Days)
★ 300.2K
97.8K
Earning Date
10-28-2026
11-16-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 10.26
N/A
EPS
N/A
★ N/A
Revenue
★ $5,636,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$1,837.59
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 35.77
N/A
52 Week Low
$8.63
$4.60
52 Week High
$26.19
$11.00

Technical Indicators

Market Signals
Indicator
DBVT
GFUZ
Relative Strength Index (RSI) 37.71 26.25
Support Level $8.78 N/A
Resistance Level $12.41 $6.34
Average True Range (ATR) 0.76 0.44
MACD -0.12 -0.06
Stochastic Oscillator 0.97 0.00

Price Performance

Historical Comparison
DBVT
GFUZ

About DBVT DBV Technologies S.A.

DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.

About GFUZ General Fusion Group Ltd. Common Shares

General Fusion Group Ltd is focused on developing fusion energy technology based on Magnetized Target Fusion (MTF), which combines magnetic confinement and mechanical compression to achieve fusion conditions. It operates a large-scale demonstration system, Lawson Machine 26 (LM26), intended to validate elements of its technology and support the development of commercial fusion power plants for electricity generation.

Share on Social Networks: